Use of In silico Methodologies to Predict the Bioavailability of Oral Suspensions: A Regulatory Approach

Use of In silico Methodologies to Predict the Bioavailability of Oral Suspensions: A Regulatory Approach

Publication: Curr Pharm Des
Software: GastroPlus®

Oral suspensions are heterogeneous disperse systems, and the particle size distribution, crystalline form of the dispersed solid, and composition of the formulation can be listed as parameters that control the drug dissolution rate and its bioavailability.

Quercetin-encapsulated magnetoliposomes: Fabrication, optimization, characterization, and antioxidant studies

Quercetin-encapsulated magnetoliposomes: Fabrication, optimization, characterization, and antioxidant studies

Authors: Kar S, Das SS, Singh SK
Publication: Eur J Lipid Sci and Tech
Software: GastroPlus®

Quercetin (QU) faces challenges in its therapeutic efficacy due to its hydrophobic nature and limited oral bioavailability.

Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products

Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products

Publication: Mol Pharm
Software: GastroPlus®

The rate and extent of colon absorption are important determinants of the in vivo performance of extended-release (ER) drug products.

Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330

Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330

Publication: CPT Pharmacometrics Syst Pharmacol
Software: GastroPlus®

APX3330 ((2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic acid), a selective inhibitor of APE1/Ref-1, has been investigated in treatment of hepatitis, cancer, diabetic retinopathy, and macular edema.

Digitalizing the TIM-1 Model Using Computational Approaches─Part Two: Digital TIM-1 Model in GastroPlus

Digitalizing the TIM-1 Model Using Computational Approaches─Part Two: Digital TIM-1 Model in GastroPlus

Publication: Mol Pharm
Software: GastroPlus®

A TIM-1 model is an in vitro gastrointestinal (GI) simulator considering crucial physiological parameters that will affect the in vivo drug release process.

Metformin inhibits digestive proteases and impairs protein digestion in mice

Metformin inhibits digestive proteases and impairs protein digestion in mice

Publication: J Biol Chem
Software: GastroPlus®

Metformin is among the most prescribed medications worldwide and the first-line therapy for type 2 diabetes.

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

Publication: Pharmaceutics
Software: GastroPlus®
Division: Simulations Plus

Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug...

Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs

Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs

Authors: Lee DY, Kang HE
Publication: Xenobiotica
Software: GastroPlus®

The pharmacokinetics of a new 5-hydroxytryptamine receptor 4 agonist, DA-6886, intended for the treatment of constipation-predominant irritable bowel syndrome...

Population Pharmacokinetics of Molnupiravir in Adults With COVID-19: Lack of Clinically Important Exposure Variation Across Individuals

Population Pharmacokinetics of Molnupiravir in Adults With COVID-19: Lack of Clinically Important Exposure Variation Across Individuals

Publication: CPT Pharmacometrics Syst Pharmacol
Division: Cognigen

Effective antiviral treatments for coronavirus disease 2019 (COVID-19) are needed to reduce the morbidity and mortality associated with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, particularly...

Virtual Docking, design and in silico ADMET profiling of novel Rho-associated protein kinases-1 (ROCK1) inhibitors

Virtual Docking, design and in silico ADMET profiling of novel Rho-associated protein kinases-1 (ROCK1) inhibitors

Publication: 2nd International Conference on Chemo and BioInformatics, Kragujevac, September 28-29, 2023, Serbia
Software: ADMET Predictor®

Overexpression of Rho-associated protein kinases has been associated with various diseases, including tumors.

Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets

Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets

Publication: Sci Rep
Software: GastroPlus®

A taste-masked chewable tablet of ciprofloxacin using ion exchange resin Kyron T-134 for enhancing compliance for the paediatric population was developed.

Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model

Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model

Publication: Clinical and Translational Science
Division: Simulations Plus

Ziritaxestat, an autotaxin inhibitor, was under development for the treatment of idiopathic pulmonary fibrosis.